Exousia Pro Will Launch a Web Series with Our New Consultant
Exousia Pro announces the addition of Dr. Marvin Hausman as a consultant and the launch of a new weekly web series titled "Ask Dr. Hausman." The clinical-stage biotech company, trading as MAJI on OTCPINK, focuses on developing exosome-based therapies for cancer and other diseases.
Dr. Hausman, who played a key role in creating Exousia AI and establishing the Glioblastoma study with UCF, will host the series where shareholders can submit questions. The program will cover updates on ongoing studies, FDA submissions, and future IND trials.
Company President Matt Dwyer highlighted Dr. Hausman's valuable network of scientific and financial professionals in the biotech sector, expressing confidence that this collaboration will open new opportunities for Exousia Pro's advancement in plant-based exosome therapies.
Exousia Pro annuncia l'ingresso del Dott. Marvin Hausman come consulente e il lancio di una nuova serie web settimanale intitolata "Chiedi al Dott. Hausman." La società biotech in fase clinica, quotata come MAJI su OTCPINK, si concentra sullo sviluppo di terapie a base di esosomi per il trattamento del cancro e di altre malattie.
Il Dott. Hausman, che ha avuto un ruolo chiave nella creazione di Exousia AI e nell'istituzione dello studio sul Glioblastoma con UCF, condurrà la serie durante la quale gli azionisti potranno inviare domande. Il programma tratterà aggiornamenti sugli studi in corso, le submission alla FDA e i futuri trial IND.
Il presidente dell'azienda, Matt Dwyer, ha sottolineato il prezioso network di professionisti scientifici e finanziari nel settore biotech di Dr. Hausman, esprimendo fiducia che questa collaborazione aprirà nuove opportunità per il progresso di Exousia Pro nelle terapie con esosomi di origine vegetale.
Exousia Pro anuncia la incorporación del Dr. Marvin Hausman como consultor y el lanzamiento de una nueva serie web semanal titulada "Pregúntale al Dr. Hausman." La empresa biotecnológica en fase clínica, que cotiza como MAJI en OTCPINK, se enfoca en desarrollar terapias basadas en exosomas para el cáncer y otras enfermedades.
El Dr. Hausman, quien desempeñó un papel clave en la creación de Exousia AI y en el establecimiento del estudio de Glioblastoma con UCF, será el anfitrión de la serie donde los accionistas podrán enviar preguntas. El programa cubrirá actualizaciones sobre estudios en curso, presentaciones a la FDA y futuros ensayos IND.
El presidente de la compañía, Matt Dwyer, destacó la valiosa red de profesionales científicos y financieros en el sector biotecnológico del Dr. Hausman, expresando confianza en que esta colaboración abrirá nuevas oportunidades para el avance de Exousia Pro en terapias con exosomas de origen vegetal.
Exousia Pro는 Dr. Marvin Hausman을 컨설턴트로 영입하고 "Ask Dr. Hausman"이라는 새로운 주간 웹 시리즈를 시작한다고 발표했습니다. 임상 단계의 바이오테크 회사로 OTCPINK에서 MAJI로 거래되며, 암 및 기타 질병에 대한 엑소좀 기반 치료법 개발에 주력하고 있습니다.
Exousia AI 창립과 UCF와의 교모세포종 연구 설립에 핵심 역할을 한 Dr. Hausman이 시리즈를 진행하며, 주주들이 질문을 제출할 수 있습니다. 프로그램은 진행 중인 연구, FDA 제출 및 향후 IND 시험에 대한 업데이트를 다룰 예정입니다.
회사 사장 Matt Dwyer는 바이오테크 분야의 과학 및 금융 전문가 네트워크를 가진 Dr. Hausman의 가치를 강조하며, 이번 협력이 식물 기반 엑소좀 치료법 개발에 새로운 기회를 열 것이라고 확신했습니다.
Exousia Pro annonce l'arrivée du Dr. Marvin Hausman en tant que consultant ainsi que le lancement d'une nouvelle série web hebdomadaire intitulée "Demandez au Dr. Hausman." Cette société biotechnologique en phase clinique, cotée sous le symbole MAJI sur OTCPINK, se concentre sur le développement de thérapies à base d'exosomes pour le cancer et d'autres maladies.
Le Dr. Hausman, qui a joué un rôle clé dans la création d'Exousia AI et l'établissement de l'étude sur le glioblastome avec l'UCF, animera la série où les actionnaires pourront poser leurs questions. Le programme couvrira les mises à jour des études en cours, les soumissions à la FDA et les futurs essais IND.
Le président de la société, Matt Dwyer, a souligné le réseau précieux de professionnels scientifiques et financiers de Dr. Hausman dans le secteur biotech, exprimant sa confiance que cette collaboration ouvrira de nouvelles opportunités pour le développement des thérapies à base d'exosomes d'origine végétale d'Exousia Pro.
Exousia Pro gibt die Ernennung von Dr. Marvin Hausman als Berater bekannt sowie den Start einer neuen wöchentlichen Webserie mit dem Titel "Ask Dr. Hausman." Das klinisch orientierte Biotech-Unternehmen, das unter dem Kürzel MAJI bei OTCPINK gehandelt wird, konzentriert sich auf die Entwicklung von Exosom-basierten Therapien gegen Krebs und andere Krankheiten.
Dr. Hausman, der eine Schlüsselrolle bei der Gründung von Exousia AI und der Einrichtung der Glioblastom-Studie mit der UCF spielte, wird die Serie moderieren, bei der Aktionäre Fragen einreichen können. Das Programm umfasst Updates zu laufenden Studien, FDA-Einreichungen und zukünftigen IND-Studien.
Der Firmenpräsident Matt Dwyer hob Dr. Hausmans wertvolles Netzwerk aus wissenschaftlichen und finanziellen Fachleuten im Biotech-Sektor hervor und zeigte sich zuversichtlich, dass diese Zusammenarbeit neue Möglichkeiten für den Fortschritt von Exousia Pro bei pflanzenbasierten Exosom-Therapien eröffnen wird.
- Strategic addition of Dr. Marvin Hausman as consultant strengthens scientific leadership
- Dr. Hausman brings valuable biotech industry connections and network access
- Company advancing in clinical-stage biotech with focus on exosome therapies for cancer treatment
- Ongoing Glioblastoma study partnership with UCF indicates research progress
- Weekly web series launch improves shareholder communication and transparency
- Consultant contract still being finalized, indicating uncertainty in engagement terms
- Early clinical stage company with no approved products yet
- No mention of financial terms or compensation for the consultant
Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.
ORLANDO, FL / ACCESS Newswire / April 30, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is launching a weekly web series titled "Ask Dr. Hausman."
Our chief science officer, Dr. Marvin Hausman, will join Exousia Pro as a consultant; his contract is being finalized now. Dr. Hausman was instrumental in creating Exousia AI and establishing the Glioblastoma study with UCF, and will assist Exousia Pro in advancing therapies using our plant-based exosomes. Exousia Pro will launch a new web series, "Ask Dr. Hausman." Shareholders will be able to email questions that Dr. Hausman will answer weekly. Dr. Hausman will also share updates on various studies conducted, our FDA submissions, and future IND trials.
Matt Dwyer, our President, stated, "Exousia Pro is very fortunate to have Dr. Hausman working with us. His rolodex of scientific and financial professionals in the biotech world is priceless. We believe that Dr. Hausman can open doors for Exousia Pro that we could never do. I met Marvin about 1 year ago and have established a strong relationship with him, and I look forward to working closely with him in advancing Exousia Pro."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
FAQ
Who is Dr. Marvin Hausman joining at Exousia Pro (MAJI) in 2025?
What is the new web series 'Ask Dr. Hausman' by Exousia Pro (MAJI)?
What role did Dr. Hausman play in Exousia Pro's Glioblastoma study?
How will Dr. Hausman benefit Exousia Pro (MAJI) as a consultant?
What type of treatments is Exousia Pro (MAJI) developing?
